Affiliation: University of Milan
- Alzheimer's disease: another target for heparin therapyLuigi Bergamaschini
Department of Internal Medicine, Geriatric Unit, Ospedale Maggiore Policlinico IRCCS, University of Milan, Italy
ScientificWorldJournal 9:891-908. 2009....
- Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's diseaseLuigi Bergamaschini
Department of Internal Medicine, Ospedale Maggiore, Instituto di Ricovero e Cura a Carattere Scientifico, University of Milan, 20122 Milan, Italy
J Neurosci 24:4181-6. 2004..By reducing the beta-amyloid load and cytotoxicity and proinflammatory activity, enoxaparin offers promise as a tool for slowing the progression of Alzheimer's disease...
- Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitroLuigi Bergamaschini
Department of Internal Medicine, Ospedale Maggiore IRCCS, University of Milan, Italy
Neurobiol Aging 23:531-6. 2002..The present data show that heparin can attenuate neurotoxic and pro-inflammatory activity of Abeta and suggest that this drug could represent a new strategy to reduce the progressive neurodegeneration in AD...
- Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liverL Bergamaschini
Department of Internal Medicine, Ospedale Maggiore IRCCS, Milan, Italy
Clin Exp Immunol 126:412-20. 2001..These results suggest that adding C1-INH to the preservation solution may be useful to reduce complement activation and tissue injury during the reperfusion of an ischaemic liver...
- Activation of complement and contact system in Alzheimer's diseaseL Bergamaschini
Department of Internal Medicine, Ospedale Maggiore IRCCS, University of Milan, Via Pace 15, 20122, Milan, Italy
Mech Ageing Dev 122:1971-83. 2001....
- The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin systemL Bergamaschini
Department of Internal Medicine, Ospedale Maggiore, IRCCS, University of Milan, Italy
Neurobiol Aging 22:63-9. 2001....
- Consumption of C4b-binding protein (C4BP) during in vivo activation of the classical complement pathwayL Bergamaschini
Department of Internal Medicine, Maggiore Hospital IRCCS, University of Milan, Milan, Italy
Clin Exp Immunol 116:220-4. 1999..The results of this study indicate that C4BP is consumed in vivo during acute, and possibly during chronic activation of the C' classical pathway, and that this protein, after interaction with C4b, not longer circulates in plasma...
- Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent mannerL Bergamaschini
Department of Internal Medicine, Maggiore Hospital, IRCCS, Milan, Italy
Clin Exp Immunol 115:526-33. 1999....
- Comparison of two immunoassays for the complement protein C4b-binding protein in health and diseaseR Coppola
Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan, Italy
Int J Clin Lab Res 25:88-92. 1995..223 +/- 67%). In these patients crossed immunoelectrophoresis showed a pattern different from that of normal individuals, which may explain the lower values found with the Laurell method...
- Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemiaM G De Simoni
Mario Negri Institute for Pharmacological Research, Milan, Italy
J Cereb Blood Flow Metab 23:232-9. 2003..Astrocyte activation induced by ischemia was not affected by C1-INH. These findings show that C1-INH displayed a potent neuroprotective action by effectively reducing ischemia-reperfusion injury...